<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04623437</url>
  </required_header>
  <id_info>
    <org_study_id>2312201522122016</org_study_id>
    <nct_id>NCT04623437</nct_id>
  </id_info>
  <brief_title>Responsible Side Effects Management in Oncology</brief_title>
  <acronym>R-SEMO</acronym>
  <official_title>Comprehensive Antineoplastic Therapy Adverse Events Monitoring and Report</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital &quot;Sestre Milosrdnice&quot;</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital &quot;Sestre Milosrdnice&quot;</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of pharmacovigilance in oncology. Monitoring and management of AEs during&#xD;
      antineoplastic treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Monitoring and management of AE's during antineoplastic treatment. Comparison of AE's&#xD;
      reported by patient with the ones recognised by the oncologist, and vice versa, during&#xD;
      antineoplastic treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Actual">September 5, 2017</completion_date>
  <primary_completion_date type="Actual">September 5, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>comparison of perspectives</measure>
    <time_frame>may 2016 until october 2016</time_frame>
    <description>comparison between patient's and oncologist's perspective on severity of AE's during antineoplastic treatment</description>
  </primary_outcome>
  <enrollment type="Actual">267</enrollment>
  <condition>Pharmacovigilance</condition>
  <condition>Oncology</condition>
  <condition>Antineoplastic Treatment</condition>
  <eligibility>
    <study_pop>
      <textblock>
        all cancer patients actively receiving systemic antineoplastic treatment, ECOG 0-2&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        all cancer patients receiving systemic antineoplastic treatment, ECOG 0-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        age &lt;18, &gt;75; other active and severe comorbidities; no solid cancer; IUC patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UHC Sestre milorsdnice</name>
      <address>
        <city>Zagreb</city>
        <state>Croatia, Europe</state>
        <zip>10 000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital &quot;Sestre Milosrdnice&quot;</investigator_affiliation>
    <investigator_full_name>Robert Šeparović</investigator_full_name>
    <investigator_title>PhD MD</investigator_title>
  </responsible_party>
  <keyword>pharmacovigilance in oncology</keyword>
  <keyword>antineoplastic treatment</keyword>
  <keyword>adverse events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

